A new speciality pharmaceutical company dedicated to women and their health has been launched through CVC Fund VI’s acquisition of Teva Pharmaceutical Industries international women’s health assets.
Women in pharma
The new company, called Theramex, will be headquartered in London, UK, and will market a broad range of innovative, branded and branded generic products across 50 countries worldwide. The portfolio of products focuses on contraception, fertility, menopause and osteoporosis, including brands such as Ovaleap, Zoely, Seasonique, Actonel, Estreva and Lutenyl.
“I am delighted and honoured to launch the new Theramex, a specialty pharmaceutical company dedicated to women and their health,” said Anish Mehta, CEO of Theramex. “Our commitment is to provide innovative, effective and safe solutions that care for and support women as they advance through each stage of their lives. We look forward to building on our strong heritage and enhancing our differentiated product portfolio to advance women’s health.”
Cathrin Petty, partner and head of European Healthcare at CVC, added: “Women’s health is a rapidly growing segment of the healthcare sector, and one which we at CVC are watching closely. I am very pleased to announce the closing of CVC Fund VI’s investment in Theramex, and look forward to working with this highly talented team. We intend to continue to grow the company through business development and further acquisitions.”